These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 23593139)

  • 1. Electroacupuncture for moderate and severe benign prostatic hyperplasia: a randomized controlled trial.
    Wang Y; Liu B; Yu J; Wu J; Wang J; Liu Z
    PLoS One; 2013; 8(4):e59449. PubMed ID: 23593139
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness and safety of electroacupuncture and its cotreatment with electronic moxibustion in the treatment of patients with moderate benign prostatic hyperplasia using alpha blocker: Study protocol for an assessor-blinded, randomized controlled clinical trial.
    Kim HB; Kim YI; Jeon JH; Kim E; Kim JY; Kwon O; Choi YE; Yang C; Han CH
    Medicine (Baltimore); 2020 Apr; 99(15):e19678. PubMed ID: 32282720
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Efficacy of electroacupuncture in treating 93 patients with benign prostatic hyperplasia].
    Yang T; Zhang XQ; Feng YW
    Zhongguo Zhong Xi Yi Jie He Za Zhi; 2008 Nov; 28(11):998-1000. PubMed ID: 19213342
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of Depth of Electroacupuncture on the IPSS of Patients with Benign Prostatic Hyperplasia.
    Yuan H; Wei N; Li Y; Yu L; Zhang Y; Ong WL; Bai N; Wang M; Fu Y; Liu Y
    Evid Based Complement Alternat Med; 2019; 2019():1439141. PubMed ID: 31915442
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effectiveness and safety of electroacupuncture and its cotreatment with electronic moxibustion in the treatment of patients with moderate benign prostatic hyperplasia using alpha blocker: An assessor-blinded, randomized, controlled pilot study.
    Kim HB; Han CH; Jeon JH; Kim E; Kwon O; Choi YE; Yang C; Park YC; Kim YI
    Medicine (Baltimore); 2022 Sep; 101(36):e30386. PubMed ID: 36086755
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of electroacupuncture at Zhongliao point (BL33) for mild and moderate benign prostatic hyperplasia: study protocol for a randomized controlled trial.
    Wang Y; Liu Z; Yu J; Ding Y; Liu X
    Trials; 2011 Sep; 12():211. PubMed ID: 21943105
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and Safety Evaluation of Transurethral Resection of the Prostate versus Plasmakinetic Enucleation of the Prostate in the Treatment of Massive Benign Prostatic Hyperplasia.
    Zhang J; Wang Y; Li S; Jin S; Zhang S; Zhao C; Yang W; Cui S; Liu Y
    Urol Int; 2021; 105(9-10):735-742. PubMed ID: 33524981
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomised, placebo-controlled, multicentre, Phase 2 clinical trial to evaluate the efficacy and safety of GV1001 in patients with benign prostatic hyperplasia.
    Moon KT; Yoo TK; Kwon SY; Ha JY; Byun SS; Kim JH; Chung JI; Kim TH; Moon HS; Kim SJ; Lee KS
    BJU Int; 2018 Aug; 122(2):283-292. PubMed ID: 29633507
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Construct validation of patient global impression of severity (PGI-S) and improvement (PGI-I) questionnaires in the treatment of men with lower urinary tract symptoms secondary to benign prostatic hyperplasia.
    Viktrup L; Hayes RP; Wang P; Shen W
    BMC Urol; 2012 Nov; 12():30. PubMed ID: 23134716
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influence of baseline variables on changes in International Prostate Symptom Score after combined therapy with dutasteride plus tamsulosin or either monotherapy in patients with benign prostatic hyperplasia and lower urinary tract symptoms: 4-year results of the CombAT study.
    Roehrborn CG; Barkin J; Tubaro A; Emberton M; Wilson TH; Brotherton BJ; Castro R
    BJU Int; 2014 Apr; 113(4):623-35. PubMed ID: 24127818
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Body Mass Index and Risk of Prostate Volume, International Prostate Symptom Score, Maximum Urinary Flow Rate, and Post-Void Residual in Benign Prostatic Hyperplasia Patients.
    Li BH; Deng T; Huang Q; Zi H; Weng H; Zeng XT
    Am J Mens Health; 2019; 13(4):1557988319870382. PubMed ID: 31426706
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Correlation of histological prostatitis with PSA, prostate volume, PSAD, IPSS, Qmax and PVR in BPH patients].
    Zhang HT; Xu Y; Chang JW; Zhang ZH; Liu RL; Ma BJ
    Zhonghua Nan Ke Xue; 2012 Mar; 18(3):208-11. PubMed ID: 22474983
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tamsulosin efficiency in treatment of benign prostatic hyperplasia evaluated by determining bladder weight.
    Milicevic S
    Med Arch; 2012; 66(6):391-5. PubMed ID: 23409519
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comparative randomized prospective study to evaluate efficacy and safety of combination of tamsulosin and tadalafil vs. tamsulosin or tadalafil alone in patients with lower urinary tract symptoms due to benign prostatic hyperplasia.
    Singh DV; Mete UK; Mandal AK; Singh SK
    J Sex Med; 2014 Jan; 11(1):187-96. PubMed ID: 24165272
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relationship between benign prostatic hyperplasia/lower urinary tract symptoms and total serum testosterone level in healthy middle-aged eugonadal men.
    Lee JH; Kim Y; Park YW; Lee DG
    J Sex Med; 2014 May; 11(5):1309-15. PubMed ID: 24612680
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and Safety of Medium-to-long-term Use of Tolterodine Extended Release with or without Tamsulosin in Patients with Benign Prostate Hyperplasia and Larger Prostate Size: A Double-blind, Placebo-controlled, Randomized Clinical Trial.
    Cai JL; Zhou Z; Yang Y; Yan YF; Jing S; Na YQ
    Chin Med J (Engl); 2016 Dec; 129(24):2899-2906. PubMed ID: 27958220
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of Clinical Outcomes of Prostatic Artery Embolization with 50-μm Plus 100-μm Polyvinyl Alcohol (PVA) Particles versus 100-μm PVA Particles Alone: A Prospective Randomized Trial.
    Wang MQ; Zhang JL; Xin HN; Yuan K; Yan J; Wang Y; Zhang GD; Fu JX
    J Vasc Interv Radiol; 2018 Dec; 29(12):1694-1702. PubMed ID: 30297313
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of tamsulosin 0.4 mg single pills for treatment of Asian patients with symptomatic benign prostatic hyperplasia with lower urinary tract symptoms: a randomized, double-blind, phase 3 trial.
    Chung JH; Oh CY; Kim JH; Ha US; Kim TH; Lee SH; Han JH; Bae JH; Chang IH; Han DH; Yoo TK; Chung JI; Kim SW; Jung J; Kim YI; Lee SW
    Curr Med Res Opin; 2018 Oct; 34(10):1793-1801. PubMed ID: 29490509
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of combined therapy with tamsulosin hydrochloride and meloxicam in patients with benign prostatic hyperplasia symptoms and impact on nocturia and sleep quality.
    Gorgel SN; Sefik E; Kose O; Olgunelma V; Sahin E
    Int Braz J Urol; 2013; 39(5):657-62. PubMed ID: 24267123
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prostatic artery embolization in treating benign prostatic hyperplasia: a systematic review.
    Teoh JY; Chiu PK; Yee CH; Wong HM; Chan CK; Chan ES; Hou SS; Ng CF
    Int Urol Nephrol; 2017 Feb; 49(2):197-203. PubMed ID: 27896579
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.